Live
FierceBiotechSalspera plans $91M IPO to fund phase 3 studies of salmonella-based cancer therapyAgilentJim Cramer on Agilent Technologies: “I Don’t Think You Need It” - Yahoo FinanceEndpoints NewsRA Capital, Forbion and Canaan appear to back Harbour's CTLA-4 partner SolsticeBioPharma DiveWith $100M, Vima pursues an oral drug for movement disordersIlluminaCapital International Inc. CA Boosts Stake in Illumina - National TodayIlluminaCapital International Inc. CA Boosts Stock Holdings in Illumina, Inc. $ILMN - MarketBeatThermo FisherBank of Montreal Can Has $247.14 Million Position in Thermo Fisher Scientific Inc. $TMO - MarketBeatThermo FisherIs Thermo Fisher Scientific (TMO) Fairly Priced After Recent Share Price Weakness? - simplywall.steLifeReplacing the immune system of the brainEndpoints NewsStudy suggests long non-coding RNA has potential as new class of genetic medicineCellImmune-microbiome coordination defines interferon setpoints in healthy humansCellBringing the genetically minimal cell to life on a computer in 4D
BioWorld Jan 22, 2026

Shanghai Qingrun Pharmaceutical Technology synthesizes new GTPase KRAS mutant inhibitors

Shanghai Qingrun Pharmaceutical Technology synthesizes new GTPase KRAS mutant inhibitors

Original
Body unavailable. Use the original source.

Directory

59 All